Biotheus

Biotheus stands out for its cutting-edge expertise in the production of monoclonal antibodies*, paving the way for targeted therapies for patients facing cancer and autoimmune diseases. Its commitment is reflected in the constant search for innovative solutions to make these advances accessible to the most vulnerable populations.

By focusing on the mass production of innovative biological products, Biotheus strives to meet unmet medical needs and improve accessibility to treatment for all.

‍Thecompany's steadily rising sales, reaching $10 million by 2021, testify to its growing impact in the healthcare field and its commitment to the fight against serious diseases.

(*): Monoclonal antibodies have revolutionized cancer treatment, offering more targeted and less toxic therapeutic options than conventional treatments such as chemotherapy. Some monoclonal antibodies can bind directly to cancer cells, disrupting their function or inducing their destruction by the immune system.
Other monoclonal antibodies can block cancer cell growth signals or inhibit tumor defense mechanisms. Some can also transport anti-cancer drugs directly to tumor sites.